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Chondrosarcomasare amongthe mostmalignantskeletaltumors.Dediﬀerentiated chondrosarcomais a highly aggressive subtype
of chondrosarcoma, with lung metastases developing within a few months of diagnosis in 90% of patients. In this paper we
performed comparative analyses of the transcriptomes of ﬁve individual metastatic lung lesions that were surgically resected
from a patient with dediﬀerentiated chondrosarcoma. We document for the ﬁrst time a high heterogeneity of gene expression
proﬁles amongthe individual lung metastases. Moreover, we reveal a signature of “multifunctional” genes that are expressed in all
metastaticlunglesions.Also,for the ﬁrsttime, we documentthe occurrence ofmassivemacrophageinﬁltrationindediﬀerentiated
chondrosarcoma lung metastases.
1.Introduction
Chondrosarcoma is the second most common malignant
skeletal tumor. One of the subtypes of chondrosarcoma—
dedifferentiated chondrosarcoma—is a high-grade pleomor-
phic noncartilaginous sarcoma, arising within a low-grade
chondrosarcoma [1] .T h em e d i a ns u r v i v a lt i m ef o rt h ed e d -
iﬀerentiated chondrosarcoma patients is 7.5 months [2].
Despite the fact that the process of metastatic dissemination
depends upon a number of highly coordinated rate limiting
steps [3, 4], it is remarkable that lung metastases develop
within a few months of diagnosis in 90% of dediﬀerentiated
chondrosarcoma patients.
There is an increasing body of evidence pointing to the
involvement of stem-like cells in the process of sarcoma’s
metastatic dissemination [5–7]. In an attempt to elucidate2 Sarcoma
the observed high frequency of dediﬀerentiated chondrosar-
coma metastases, we developed a hypothesis that dediﬀer-
entiated chondrosarcoma-initiating cells might have some
characteristics of stem-like cells. We further hypothesized
that such dediﬀerentiated chondrosarcoma-initiating cells
might exhibit at least two predominant features: multi-
potentiality, as one of the stem cell characteristics, which
would explain pleomorphic histology of dediﬀerentiated
chondrosarcoma [1, 8], and “multifunctionality”-expression
of a set of “multifunctional” genes, which would explain fast
progression of dediﬀerentiated chondrosarcoma through all
the rate-limiting steps required for metastatic dissemination.
Based on the hypothetical multipotentiality of dediﬀer-
entiated chondrosarcoma-initiating cells, we suspected that
there would be a high degree of heterogeneity among metas-
tasesofasinglepatient.Thiswouldexplainatleastinpartthe
notorious untreatability of dediﬀerentiated chondrosarcoma
lung metastases. Indeed, by using Serial Analysis of Gene
Expression (SAGE) we found a high degree of heterogeneity
a tt h eg e n ee x p r e s s i o nl e v e la m o n gt h ed i ﬀerent lung metas-
tases from a single dediﬀerentiated chondrosarcoma patient.
Also, we found a signature of “multifunctional” genes in
all the metastatic lesions. Remarkably, most of these genes
are not only known to be involved in metastatic dissem-
ination in other tumor types but also to be expressed in
mesenchymal stem cells. Analysis of this gene signature
predicted the occurrence of a leukocyte inﬁltration in these
metastases. Indeed, for the ﬁrst time, we have documented
t h eo c c u r r e n c eo fam a s s i v em a c r o p h a g ei n ﬁ l t r a t i o ni nt h e
dediﬀerentiated chondrosarcoma lung metastases.
2.Materialsand Methods
2.1. Patients Involved in This Study (IRB Number 199703227).
Patient A was a female diagnosed at 45 years of age with a
pelvic dediﬀerentiated chondrosarcoma. Following surgical
resection, the patient received pelvic radiation therapy at the
site of the primary tumor (66Gg—35 sessions). Two months
following resection, the patient was diagnosed with lung
metastases. The patient received chemotherapy (Adriamycin
(30mg/m2—day 1, 30mg/m2—day 2) and Cis-platinum
(120mg/m2—day1,200mg/m2—day2)),whichwasadmin-
istered once every three weeks for a period of nine weeks.
Following chemotherapy the patient underwent excision of
the metastatic lesions.
Patient B was a male diagnosed at twenty eight years of
agewitharecurrentintrapelvicchondrosarcoma. Hewas ini-
tially admittedtothe hospitaland diagnosed withintrapelvic
chondrosarcomaGradeI,whichwassurgicallyresected.Over
the next 10 years, the patient experienced local recurrences
nearly every year. During this period the recurrent tumor
progressed from histologic grade I to grade II. Remarkably,
no evidence of distant metastatic disease has been reported
to date.
2.2. Histology and Immunohistochemistry. Four micron-
thick sections were prepared from formalin-ﬁxed, paraﬃn-
embedded tissue obtained from the pelvic resection and
initial lung metastasis of patient A and two separate recur-
rences from patient B. Sections were either stained with
hematoxylin and eosin using standard procedures or were
subject to immunohistochemical staining. Immunohisto-
chemical stains were performed using the Envision+ Dual
Link System Peroxidase Kit (Dako) using primary antibodies
directed against CD68 (monoclonal KP1, Dako, dilution
1:80) or CD15 (monoclonal MMA, Cell Marque, dilution
1:50). Antigen retrieval techniques involved digestion in
proteinase K for ﬁve minutes for the KP1 antibody or
pressure cooking for 30 minutes for the MMA antibody.
The sections were then counterstained with hematoxylin.
Appropriate positive control tissues were used, and antibody
was omitted in negative control slides.
2.3. Establishment and GeneralMaintenance of Metastatic and
Nonmetastatic Cell Lines. Fresh tissue samples from patient
A’s metastatic lesions were divided into 1mm3 portions and
incubated at 37◦C for 30 minutes with testicular hyalu-
ronidase type IA (Sigma-Aldrich) (0.1%, w/v) in growth
medium that contained heat inactivated fetal bovine serum
(Life Technologies Gibco) (10%), Dulbecco’s modiﬁed Eagle
medium, glucose (4.5gm/L), and HEPES buﬀer (25mM)
solution. The tissue samples were then further treated
with collagenase type 1A (Sigma-Aldrich) (0.05%, w/v) and
dispase (Life Technologies Gibco) (0.05%, w/v) in growth
medium containing gentamycin (50ug/mL), incubated at
37◦Ci naC O 2 (5%) incubator for 21 hours. Monodispersed
cellswere obtainedfollowing ﬁltration oftheenzyme-treated
tissue through 70mkm and 40mkm screens and frozen
in diemethylsulfoxide/heat-inactivated fetal bovine serum
(10%/90%, v/v). Metastatic cell lines (Met.-cell lines) were
established from these cells after culturing in RPMI-1640
supplemented with 10% FBS and 0.1% gentamycin sulfate
(Gemini Bioproducts). Cells were cultured through four
doublings to yield 2 × 107 cells.
Fresh tissue samples from patient B’s recurrent tumors
were divided by gross analysis into the cartilaginous and
ﬁbro-cartilaginous samples for tissue-cell isolation. The pro-
tocol described previously was used for establishment and
maintenance of the two resulting cell lines (NM-cell lines).
All the cell lines were routinely screened for mycoplasma
contamination using a PCR-based ELISA detection assay
(Roche). Cell manipulations were always performed on 80–
90% conﬂuent cultures for consistency.
2.4. Invasion Assay. The Membrane Invasion Culture System
(MICS) chamber was used to evaluate the degree of tumor
cell invasion through ECMs in vitro as described previously
[9]. Percent invasion was corrected for proliferation and
calculated as total number of invading cells from lower
chamber divided by the total number of cells seeded in the
upper chamber ×100. Six wells were dedicated to test each
cell line (Supplemental Table 5c) per experiment, and each
experiment was repeated at least 3 times. The data generated
from these studies were statistically analyzed for “one-way
analysis of variance” using the statistical package (ANOVA
analysis) of the Microsoft Excel spreadsheet program.Sarcoma 3
Table 1: Panel of SAGE libraries.
Library name Tumor location SAGE tags Pathology
Met.-cell lines
UIFK0 (Met. 1) Right middle lobe, upper anterior metastatic
lesion 87957
Dediﬀerentiated chondrosarcoma
lung metastases
UIGP0 (Met. 2) Right upper lobe, apical lateral metastatic lesion 108331
UIGD0 (Met. 3) Right lower lobe, middle diaphragmatic
metastatic lesion 109862
UIEK0 (Met. 4) Right lower lobe, middle posterior metastatic
lesion- 83522
UIGX0 (Met. 5) Left lower lobe, diaphragmatic anterior metastatic
lesion 88439
(NM-) cell lines
UIGE0 (NM. 1) Interior medial aspect of the pelvis.
Fibrocartilaginous sample 77757 Recurrent nonmetastatic
chondrosarcoma, grade 2
UIFU0 (NM. 2) Interior medial aspect of the pelvis. Cartilaginous
sample 77019
2.5. RNA Extraction. Total RNA for RT-PCR was isolated
fromtheculturedcellsusingRNazolB(BiotecxLaboratories,
Inc., Houston, TX, USA) according to the manufacturer’s
instructions. PolyA+ RNAfortheSAGElibraryconstructions
was isolated from the cultured cells using Dynabeads mRNA
DIRECT kit (Dynal A.S, Oslo, Norway) according to the
manufacturer’s instructions.
2.6. SAGE Library Construction. Double-strand cDNA was
synthesized from RNA isolated from Met. 1–5 and NM. 1
and 2 (Table 1) as it has been previously described [10].
The SAGE protocol utilized for library construction in this
studywasa modiﬁcationofa previouslydescribedprocedure
[11]. Speciﬁcally, we modiﬁed the SAGE procedure by using
T4 DNA Polymerase to make blunt end concatameres,
and subsequently cloned them into a blunt ended pUC18
plasmid. After electroporation and overnight growth on
plates, we utilized a sequencing protocol without the PCR
size selection step, required in the original protocol. We used
SAGE 2000 software (http://www.sagenet.org/)t oe x t r a c tt h e
SAGE tags and to calculate the frequency at which each tag
is seen within a SAGE library. More than 77,000 tags were
sequenced from each library and the size of each library was
normalized to 100,000 tags. After the normalization, all the
tags were mapped to NCBI’s UniGene clusters, using the
SAGE GENIE database [12].
We have combined and averaged cluster sizes of identical
tags from thenormalized NM.1 and NM.2 libraries in order
to create a virtual NM-library of the nonmetastatic tumor.
All SAGE libraries were submitted to the NCI Cancer
Genome Anatomy Project SAGE library collection. Pairwise
comparisons of the normalized SAGE libraries were done by
applying the z-test [13]. The normalized SAGE data were
used as the input for the Gene Spring 7.3.1 program (Silicon
Genetics, Redwood City, CA, USA), which allows multiﬁlter
comparisons and generation of conditional (hierarchical)
trees.
2.7. DNA Sequencing. Sequencing reactions were performed
with the ABI PRISMdRhodamine terminator cyclesequenc-
ing kit and −40 M13 Forward primers. Reaction products
were electrophoresed on an ABI PRISM 3700 DNAAnalyzer.
2.8. Datasets for the Functional Analysis
2.8.1. Genes Commonly Expressed in Metastatic Lung Lesions
of Patient A. We selected the genes (deﬁned as unique
EntrezGene identiﬁers) that were expressed in all ﬁve librar-
ies, derived from the Met.-cell lines (see Section 2.6). This
dataset contained1,488“common”genes,including59genes
of ribosomal proteins (see below).
2.8.2. Genes Expressed in the Nonmetastatic Tumor of Patient
B. This dataset contained 3,249 genes that were commonly
expressed in the two libraries composing the virtual NM.-
library (see Section 2.6).
2.8.3.Literature-Based List ofGenesPreviouslyAssociatedwith
Metastasis. Genes in this list were annotated by GeneGo
based on PubMed searches. The list contained 339 genes
associated with the process of metastatic dissemination
(Table 2 see in Supplementary Material available online at
doi: 10.1155/2012/820254).
2.8.4. Genes with Diﬀerential Expression in the Metastases.
Genes in this list were expressed in all ﬁve libraries derived
from Met.-cell lines and diﬀerentially expressed in the
virtual NM.-library. This dataset contained 158 diﬀerentially
expressed genes: 88 upregulated and 70 downregulated in all
the Met.-cell lines. Interestingly, 26 of the 70 downregulated
genes encode ribosomal proteins (Supplementary Table 2).
2.8.5. Genes from “Metastasis-Related” Processes. The list
contained genes annotated by GeneGo from eight functional4 Sarcoma
categories of relevance to metastasis, namely, cell motility,
(126 genes), cell adhesion (483 genes), chemotaxis (125
genes), blood coagulation (81 genes), cell proliferation (302
genes),ECMremodeling(99genes),angiogenesis(66genes),
and antiapoptosis (118 genes).
2.8.6. “Multifunctional” Genes. The criterion utilized for
selection was “multifunctionality”; that is, the selected pro-
teins should belong to at least two of the 8 functional cate-
goriescompiledbyGeneGo(see Section 2.8.5).Atotalof161
proteins were selected and herein coined, “multifunctional”
grid. Interestingly, 36 of such “multifunctional” genes are
also in the list of genes from the metastasis associated liter-
ature (see Section 2.8.3).
2.9. Gene List Enrichment Analysis. First, the lists of signiﬁ-
cantly diﬀerentially expressed genes among diﬀerent metas-
tases were generated by conducting pairwise comparisons
betweenthegenesexpressedinUIFK0-Met.1(4,205clusters)
and those expressed in each of the other metastases, that is,
Met. 2–5.Next, to evaluatethe enrichment ofthe “metastasis
associated” and the “multifunctional” genes in such lists of
signiﬁcantly diﬀerentially expressed genes, a simulation of
randomly chosen clusters was carried out. For each iteration
of the simulation, 105 or 52 clusters were randomly cho-
sen from the total 4,205 clusters from UIFK0-Met. 1 (see
Section 3). Out of these 105 or 52 randomly chosen clusters,
the numbers of clusters that appeared in the lists of signif-
icantly diﬀerentially expressed genes were determined and
the corresponding ratios for these clusters were calculated. A
total of 100,000 iterations were performed and the average
ratios were calculated. These average ratios were used as
baseline levels in order to compare with the representations
of the speciﬁc 105 “metastasis-associated” and the 52“multi-
functional” genes. In order to determine the signiﬁcance of
the enrichment, one sample binomial test was carried out
for each of the corresponding comparisons. The R statistical
package and Microsoft Excel software were used to perform
these statistical calculations.
2.10. Functional Analysis of SAGE Data. For functional anal-
ysis, we applied an integrated human data mining suit—
MetaCore (GeneGo, Inc.)—which has been described else-
where [14].
2.11. Real-Time PCR. Real-time quantitative reverse tran-
scription-polymerase chain reactions (QRT-PCRs) were per-
formed using an IQ5 Cycler (Bio-Rad Laboratories, USA)
according to the manufacturer’s instructions. Primers were
designed using the Primer Express program version 1.5
(Applied Biosystems, CA, USA) and obtained from Inte-
grated DNA Technologies (Coralville, IA, USA; Supplemen-
tary Table 1). The speciﬁcity of the primers was documented
by RT-PCR and resulted in a single product with the
desired length. cDNAs were constructed using IScript cDNA
synthesis kit (Bio-Rad Laboratories, USA) according to the
manufacturer’s instruction. Reactions were performed using
IQ SYBR Green Supermix kit (Bio-Rad Laboratories, USA)
according to the manufacturer’s instruction. Each reaction
was performed in triplicate, using 250nM primers, cDNA
sample corresponding to 0.25ng of total RNA, in a total
volume of 25μL. 100nM primers for 18S rRNA from the
TaqMan Ribosomal RNA Control Reagents kit (Applied
Biosystems, CA, USA) were used as a reference for each of
the cDNA samples. The PCR conditions were as follows: one
cycle at 95◦C for 3min, 34 cycles at 95◦C for 30sec, 55◦C
for 30sec, 72◦C for 30sec, followed by a melting curve from
55◦Ct o9 5 ◦C. A standard curve was generated using serial
dilutions of the template cDNA for the reference gene and
for each gene of interest. The eﬃciencies of ampliﬁcation
for each gene were calculated using software provided by the
IQ5 Cycler. An equimolar pool of cDNA samples from two
NM.-cell lines was used as a calibrator. We used the Pfaﬄ
method to calculate the relative gene expression levels (Bio-
RadLaboratories,Inc.Real-Time PCRApplicationsGuidep-
43).
3.Results
3.1. Initial Histological Analysis of the Primary Tumor and
the Metastases. A pelvic resection specimen from the patient
A( Section 2) demonstrated the typical histological features
of a dediﬀerentiated chondrosarcoma (Figure 1(a)). Areas
of low-grade chondrosarcoma were abruptly juxtaposed to
distinct areas of high-grade spindle cell sarcoma, charac-
terized by a cellular proliferation of highly pleomorphic
spindle to stellate cells with anaplastic and hyperchromatic
nuclei. Focal osteoid matrix formation was noted within the
dediﬀerentiatedfoci(Figure 1(b)).Incontrasttotheprimary
tumor specimen, the metastatic foci consisted entirely of
t h eh i g h - g r a d ed e d i ﬀerentiated portion of the tumor, and
no evidence of the low-grade chondrosarcoma component
was identiﬁed (Figure 1(c)). Similarly to the primary dedif-
ferentiated component, focal osteoid formation was present
within the metastases (Figure 1(d)).
3.2. Invasion Assay. T oe v a l u a t et h ed e g r e eo ft u m o rc e l l
invasion of the metastatic and nonmetastatic cell lines we
used the MICS chamber as described previously [9]. Met.
2- and Met. 3-cell lines were excluded from the assay due
to limited amount of cells. All the remaining metastatic cell
linesshowed signiﬁcantlyhigherpercentageofinvadingcells,
after 24 hours in the invasion assays, in comparison with
both NM cell lines (Supplementary Table 5c).
3.3. Molecular Analyses of the Lung Metastases. Aiming to
identify potential diﬀerences in expression among the ﬁve
metastases, we isolated RNA from the ﬁve cell lines that were
established from each of the metastases and SAGE libraries
were constructed. In order to identify relationships among
the Met. cell lines, we conducted a hierarchical clustering
analysis [15] using GeneSpring with the standard correlation
algorithm. Asitcan beseen in Figure 2,M et.1andM et.2ar e
the farthest apart; hence they exhibit the most diﬀerence in
expression pattern.Sarcoma 5
(a) (b)
(c) (d)
Figure 1: (a) The pelvic resection specimen of dediﬀerentiated chondrosarcoma demonstrated low-grade component (left) abruptly jux-
taposed to high-grade dediﬀerentiated component (right) (10x, H&E). (b) Focal osteoid formation was present within the dediﬀerentiated
component(20x,H&E). (c) The lung metastasesconsistedentirely of the dediﬀerentiated component of the primary tumor(10x, H&E). (d)
Focal osteoid formationwas noted within the metastatic tumor (20x, H&E).
Next we conducted pairwise comparisons between the
genes expressed in Met. 1 (4,205 genes) and those expressed
in each of the other metastases, that is, Met. 2–5 (Supple-
mental Table 4A). This was done with the goal of identifying
statistically signiﬁcant diﬀerences and similarities in gene
expression among the ﬁve lesions. We then derived a set of
“metastases-associated” genes that were expressed in Met.
1 (105 genes) by intersecting the genes in Section 2.8.3
(“metastasis-associated” genes) with the genes expressed in
Met. 1. Similar pairwise comparisons were then performed
between the subset of 105 “metastasis-associated” genes
identiﬁed in Met. 1 and those expressed in each of the other
metastases (Supplementary Table 4B). Last, we derived a list
of “multifunctional” genes expressed in Met. 1 (52 genes)—
by intersecting the genes in Section 2.8.6 (“Multifunctional”
genes) with those expressed in Met. 1—and performed
pairwise comparisons between themand the genesexpressed
in each of the other metastases (Supplementary Table 4C).
The results from these sets ofpairwise comparisons show
that the percentage ofdiﬀerentially expressed genesis greater
in the subset of 105 “metastasis associated” genes and in
the subset of 52 “multifunctional” genes (P<0.001 for
all four comparisons) (Supplementary Tables 4B and C)
than the respective percentages of diﬀerentially expressed
genes when all the genes that are expressed in the metastases
are compared. The aforementioned P values were calculated
based uponcomputationalsimulationanalyses of105and 52
randomly chosen clusters (data not shown).
To clarify that the diﬀerentially expressed genes are not
derived from the low copy number gene population [10],
we further assessed whether there was a bias in the cluster
sizes of SAGE tags corresponding to transcripts that were
signiﬁcantly diﬀerentially expressed relative to those of the
transcripts that did not exhibit diﬀerential expression in
the metastases. Overall, signiﬁcantly diﬀerentially expressed
genes tended to have larger cluster sizes (SAGE tag average
mean value 27.5) than those with no signiﬁcant diﬀerence
in expression (SAGE tag average mean value 6.77). Similar
trends werealso observedforthe“metastasis-associated” and
for the “multifunctional” genes; that is, SAGE tags cor-
responding to signiﬁcantly diﬀerentially expressed genes
tended to have larger cluster sizes (SAGE tag average mean
value 43.27 and 59.1, resp.), in comparison to those with no
signiﬁcant diﬀerence in expression (SAGE tag average mean
value 17.74 and 13.04, resp. (Supplementary Table 3)).
3.4. Analysis of “Multifunctional” Genes Expressed in the Lung
Metastases. Inorderto identify a “multifunctional” genesig-
nature in the Met. cell lines, we intersected “Section 2.8.6”
(“multifunctional” grid—161 genes) with “Section 2.8.1
(commonly expressed genes in the Met.-cell lines-1488
genes). This analysis revealed 38 “multifunctional” genes,6 Sarcoma
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Figure 2: Hierarchical clustering analysis of the SAGE libraries,
generated from the Met.-cell lines, using the standard correlation
algorithms (GeneSpring). ∗Cluster size ≥ 2.
herein referred to as the “multifunctional signature” of the
Met.-cell lines (Figure 3(a), Supplementary Table 2).
I n t e r e s t i n g l y ,w ef o u n dan u m b e ro fg e n e si nt h i sm u l -
tifunctional signature (PLAU, CCL2, IL8, CXCL1, CD44),
which had been previously shown to be involved in the re-
cruitment of leukocytes [16–19]. Based on this observation,
we suspected that recruitment of leukocytes might be
involved in the process of metastatic dissemination in dedif-
ferentiated chondrosarcoma (see the following). In parallel,
we intersected “Section 2.8.6”w i t h“ Section 2.8.2”( g e n e s
expressed in the virtual NM-cell line—3249 genes) and
found 46 “multifunctional” genes (Figure 3(a), Supplemen-
tary Table 2). In total, there were ﬁfty ﬁve genes in the
two “multifunctional” signatures combined: 8 genes were
uniquelyexpressed inthe Met.-cell lines (averagemean value
32.7), and 17 genes were uniquely expressed in the virtual
NM-cell line (average mean value 23.9). It is conceivable
that an “eﬀective” combination of “multifunctional” genes
m i g h te x i s t ,i nt h a tt h e ym a ya c ts y n e r g i s t i c a l l ya n dp r o v i d e
functional redundancy to promote or to facilitate the process
of metastatic dissemination (see the following).
Next, we determined which of the 38 genes in the “mul-
tifunctional signature” of metastasis were diﬀerentially ex-
pressed in the nonmetastatic tumor, by intersecting it with
the genes in “Section 2.8.4” (158 genes with signiﬁcantly
altered expression in the metastases compared to the non-
metastatic tumor). This analysis revealed 15 diﬀerentially
Table 2: “Biased multifunctional signature” of dediﬀerentiated
chondrosarcoma lung metastases.
Upregulated in Met.-cell lines
Gene name Gene symbol
Plasminogenactivator, Tissue PLAT∗
Plasminogenactivator, Urokinase PLAU∗
Interleukin 8 IL8∗
Chemokine (C-C motif) ligand 2 CCL2
Integrin, beta 1 ITGB1
Actin, beta ACTB
Vinculin VCL
Drebrin 1 DBN1∗
Moesin MSN∗
Tissue factor pathway inhibitor 2 TFPI2∗
Caveolin 1 CAV1
Caveolin 2 CAV2∗
Tenascin-C TNC ∗
Downregulated in Met.-cell lines
Transforming growth factor, beta-induced, 68kDA TGFBI
Serpin peptidase inhibitor, clade E, member 2 SERPINE2
∗Genes uniquely expressed in the metastases.
expressed “multifunctional” genes—herein referred to as
the “biased multifunctional signature”—seven of which
were diﬀerentially expressed while the remainder eight were
uniquely expressed in the metastases (Figure 3(b), Table 2).
Interestingly, only 10.6% of the genes commonly expressed
in the Met.-cell lines were diﬀerentially expressed in the
virtual NM-cell line (158/1488 commonly expressed in the
metastases). In contrast, 39.5% of “multifunctional” genes
commonly expressed in the Met.-cell lines were found to
be diﬀerentially expressed in the virtual NM-cell line (15/38
multifunctional genes) (Figure 3(b)).
The diﬀerential expression of a subset of genes in the
“biased multifunctional signature” was validated by quanti-
tative real-time PCR (Supplementary Table 1). We used the
15 genes of the “biased multifunctional signature” as an
input list for generation of biological networks [14] (Supple-
mentary Figure 1).
3.5. Immunohistochemistry of the Lung Metastasis. Based
upon our analysis of the “multifunctional signature” of me-
tastasis, asaforementioned,wesuspectedthatleukocyteinﬁl-
tration might have been involved in the metastatic dissem-
ination of patient’s A dediﬀerentiated chondrosarcoma, a
phenomenon that has been documented to occur in diﬀer-
ent types of tumors, including sarcomas [20–23]. Hence,
we decided to stain sections of the primary tumor and
of all ﬁve metastases of patient A as well as sections of
the primary tumor obtained from patient B, with antibod-
ies against CD68, a macrophage-speciﬁc antigen, and CD15,
to detect neutrophils. Both low- and high-grade sections of
patient A’s primary tumor contained only rare intra-tumoral
macrophages (Figure 4(a), panels A and B). In contrast,
immunohistochemical stains of all metastatic lung lesionsSarcoma 7
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Figure 3: (a) Identiﬁcation of “multifunctional” signatures. (b) Identiﬁcation of “biased multifunctional” signature.
analyzed in this study showed a massive macrophage inﬁl-
trate (Figure 4(a)(C)). CD68-positive cells were fairly evenly
distributed throughout the metastatic nodules and the cell
density averaged approximately 180 per 40x high-power
ﬁeld. In contrast to the metastatic tumors, the locally recur-
rent, nonmetastatic tumor from patient B contained only
few macrophages in the adjacent interstitial tissue and no
signiﬁcant intratumoral macrophages in either the original
or recurrent tumor (Figure 4(b), panels A and B). Immuno-
histochemical stains for CD15showed no signiﬁcant intratu-
moralneutrophilicinﬁltratewithineithertheprimarytumor
or in the metastatic nodules of patient A, as well as in the
nonmetastatic tumor of patient B (data not shown).
4.Discussion
As expected, the metastatic foci consisted entirely of the
high-grade dediﬀerentiated portion of the tumor, with no
evidence of the low-grade chondrosarcoma component.
The cellular compositon of the metastases correlates with
the results of the invasion assay, where metastatic cell lines
showed signiﬁcantly higher percentage of invading cells in
comparison with both NM cell lines.
Despite the fact that the metastatic cell lines were gener-
atedfromthedediﬀerentiatedcells,theyexhibitedexpression
of a number of genes that are considered to be chondrocyte
markers [24–33] (Supplementary Table 5a). As expected,
however, the majority of the chondrocyte markers were
downregulatedinthemetastaticcelllinesincomparisonwith
the two NM cell lines, consistent with the status of dediﬀer-
entiation. Additionally, we found expression of genes such
as Collagen, type I, alpha 1 (COL1A1), Exostoses (multiple)
1 (EST1), Exostoses (multiple) 2 (EXT2), Vimentin (VIM),
and Osteoprotegerin (TNFRSF11B), which are known to be
involved in development of conventional chondrosarcomas
[34–38] (Supplementary Table 5a).
Despite the limitations arising from the fact that no sam-
ples were available for analysis of the primary tumor, and
that only restricted amounts of bulk tissue couldbe obtained
from the metastatic lesions, our ﬁndings have shed some8 Sarcoma
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(C)
(a)
(A) (B)
(b)
Figure 4: (a) CD68 stainingdemonstrates rare intratumoralmacrophages in both the high-grade (A) and low-grade (B) components of the
primary tumor from the patient A, whereas numerous intratumoral macrophages were present throughout the lung metastases (C) (40x,
CD68). (b) (A) Stains for CD68 reveal very few intratumoral macrophages within a primary low-grade chondrosarcoma from the patient B
(40x,CD68). (B)CD68 stainsofthe localrecurrence highlighta few macrophages inthe adjacent ﬁbroconnective tissue but no intratumoral
macrophages (40x, CD68).
light to the molecular mechanisms underlying metastasis in
dediﬀerentiated chondrosarcoma.
For the ﬁrst time we documented a high heterogeneity at
the gene expression level among individual lung metastases
of a dediﬀerentiated chondrosarcoma patient. The hetero-
geneityis evengreater for the “metastasis associated” and the
“multifunctional” genes (Supplementary Table 4A–C), thus
suggesting that it is indeed of “functional nature”.
Thereisapossibilitythatthehighdegreeofheterogeneity
observed among the metastases might be due to the manip-
ulations that they were subjected to after resection from the
patient. We believe this not to be the case because the ﬁve
metastases were treated identically and, importantly, their
cells were cultured under the same conditions and were only
allowed to go through four doublings. Moreover, all ﬁve
cultures were initiated at the same time, following the same
procedures and utilizing the same reagents. Accordingly, it is
noteworthy that of the 59 genesencoding ribosomal proteins
found to be expressed in each of the ﬁve metastases, there
is a group of 26 genes that were consistently downregulated
relative to the virtual NM-cell line (Supplemental Table 2).
Such consistent downregulation of the ribosomal proteins in
the metastases serves to validate both the experimental and
the statistical methods utilized in this study.
There is also the possibility that theheterogeneity in gene
expression observed among the metastases might be due to
occurrence of diﬀerent aberrations in the karyotypes of their
cells. However, we did not ﬁnd any signiﬁcant karyotypeSarcoma 9
aberrations in the Met.-cell lines, except for Met. 5, in which
two translocations t (5; 13) (q11.2; q32) and t (17; 18) (q23;
p11.31) were identiﬁed in about 25% of the cells (data not
shown; Dr. Shivanand R Patil, personal communication).
Lastly, the heterogeneity of expression might have re-
sulted from the fact that each of the ﬁve lung lesions had a
diﬀerent “traveling history”. They might have been derived
from diﬀerent parts of the primary tumor and hence ex-
posed to diﬀerent microenvironments, which may also have
occurred during lung colonization. It is conceivable that
such a high level of heterogeneity observed among the
metastasesmightcontributeatleastinparttotheirnotorious
untreatability.
Remarkably, most of the genes in the “biased multifunc-
tional signature” are known to be involved in metastatic
dissemination in diﬀerent types of cancer. In particular,
upregulation of urokinase (PLAU) was associated with an
increased rate of metastasis and a decreased metastasis-free
survival in 114 cases of chondrosarcoma of bone [39]. Our
results, which revealed upregulation of PLAU and of tissue
plasminogen activator (PLAT) in all Met.-cell lines, are in
accordance with those reported by H¨ ackel and colleagues
[40]. They found that the high-grade dediﬀerentiated com-
ponents of the tumors—but not the low-grade components
of the same tumors, nor conventional chondrosarcomas-
exhibited robust, diﬀuse coexpression of PLAU and PLAT.
Other genes such as IL8, ITGB1, MSN, TFPI2, CAV1, and
TGFB1 are also in Section 2.8.3“metastasis associated genes”
(Table 2, Supplementary Table 2) [41–47]. Furthermore, all
thegenesin thenetwork shown in (SupplementaryMaterials
Figure 1), with the exception of AP-1, are “multifunctional”
and expressed in the Met.-cell lines. It is noteworthy that
three of these genes—FN1, ILK, and CD44—are diﬀeren-
tially expressed in four of the ﬁve Met.-cell lines, relative to
the virtual NM-cell line. FN1, CD44, and CTNNB1 (beta-
catenin) are also in the list of “metastasis-associated genes”
(Supplementary Table 2) [19, 48–52]. Minn and colleagues
[53] found MMP1, CXCL1, and TNC among 18 of the
most signiﬁcant (P<0.05) genes in a lung metastasis
signature. All three are in the “multifunctional” signature of
dediﬀerentiated chondrosarcoma lung metastases—MMP1
and CXCL1 were signiﬁcantly diﬀerentially expressed in 4
out of 5 metastases; TNC was diﬀerentially expressed in all
5 metastases and it is also a component of the “biased”
signature). The authors also showed that combinations
of MMP1 and CXCL1 could synergistically enhance lung
colonization. Also, certain genes in the “biased” signature
of dediﬀerentiated chondrosarcoma lung metastases, such as
CCL2 and IL-8, were found to be signiﬁcantly upregulated
in primary tumors of nonsmall cell lung carcinoma with
known history of lung metastases [54]. PLAU, another gene
in the dediﬀerentiated chondrosarcoma- “biased” signature,
was found to be involved in dissemination of bladder cancer
lung metastases [55].
Noteworthy, majority of the genes from the network
(Supplementary Figure 1)—PLAU, PLAT, TFPI2, ITGB1,
CCL2, IL8, Cav1, FN1, ILK, and CD44—are known to be
expressed in mesenchymal stem cells (MSCs) [56–61], as
well as in other adult stem cells. Moreover, around 36% of
the genes diﬀerentially expressed during chondrogenic dif-
ferentiation of MSC [62] also had altered expression in the
dediﬀerentiated chondrosarcoma metastases (27/74 genes
diﬀerentially expressed in MSC) (Supplementary Table 5b).
Some of these genes were found to be expressed at high
level in both studies. Interestingly, the majority of the
downregulated genes listed in this table are considered to
be chondrocyte markers (AGC1, COL1a1, COMP, SPARC,
Col3a1, BGN, FMOD) [24–27]. Hence, as expected, they
did become downregulated during the dediﬀerentiation of
chondrosarcoma and/or upregulated during the chondro-
cytic diﬀerentiation of MSC. FN1 was upregulated during
the chondrogenic diﬀerentiation of MSC but in our study it
wasupregulatedinthemetastases (SupplementaryTable 5b).
In concordance with our data, FN1 was also upregulated in
diﬀerent metastatic chondrosarcomas [28].
Nonetheless,itremainstobedeterminedifstem-likecells
are indeed involved in the process of metastatic dissemi-
nation in dediﬀerentiated chondrosarcomas, and if “multi-
functional” genes enable the rate-limiting steps of metastatic
dissemination.
Although unlikely, it is conceivable that the fact that
patient A had already been exposed to cytotoxic chemother-
apy when the lung lesions were resected might have inﬂu-
enced our results. We ﬁnd it to be unlikely because—with
the exception of vinculin—none of the genes in the “biased
signature” was upregulated in a SAGE library derived from
the metastasis-free lung tissue sample obtained from the
same dediﬀerentiated chondrosarcoma patient (Malchenko,
S. and Soares, MB, personal communication), relative to
the nonmetastatic tumor. Moreover, in other large-scale
gene expression studies, none of the genes in the “biased
multifunctionalsignature”exhibitedalteredexpression upon
exposure to a similar treatment regimen [63, 64].
This is the ﬁrst report of a macrophage inﬁltration in
lung metastases of dediﬀerentiated chondrosarcoma. It has
been shown that macrophages, derived from circulating
monocytes, represent a major component of the leukocyte
inﬁltration in a tumor microenvironment [20]. An increase
in the density of tumor-associated macrophages (TAMs) was
correlated with poor prognosis in the majority of clinical
studies in diﬀerent types of cancer, including sarcomas [20–
22]. Also, tumor overexpression of macrophage chemoat-
tractants has been shown to correlate with poor prognosis
[23].Notwithstanding these ﬁndings, we cannot excludethat
the observed macrophage inﬁltration represents either a spe-
ciﬁc antitumor defense mechanism or a general “physiologi-
cal”reaction onlocalmicroenvironmental changescausedby
the metastases [65]. However, the evenly high macrophage
density that was observed all throughout the metastatic
nodules is arguably not consistent with such interpretation.
Functional redundancy playsan important role in cancer
development [66]. It is conceivable that coexpression of
certain genes in the “multifunctional” signature of dediﬀer-
entiated chondrosarcoma metastases—such as CD44, PLAU,
CXCL1, CCL2, and IL8—might increase the level of func-
tional redundancy in the process of macrophage recruitment
to the dediﬀerentiated chondrosarcoma metastases [16–19,
67]. Functional synergy might also play an important role10 Sarcoma
in cancer development. Quite intriguing are the examples
of synergy between some of these “multifunctional” genes—
CCL2 and IL8, MMP1 and CXCL1 [16, 53, 68], and PLAT
and PLAU [69]—suggesting that the synergizing capacity of
“multifunctional” genes might bear signiﬁcance to the pro-
cess of metastatic dissemination. Unfortunately, due to the
restricted amount of tissues, as it was mentioned previously,
we did not have an opportunity to directly correlate protein
expression of the “multifunctional” genes with macrophage
recruitment in the metastatic lesions. Also, since there
is no in vivo model of dediﬀerentiated chondrosarcoma
lung metastasis, we did not have an option to analyse the
involvement of the “multifunctional” genes in the process of
metastatic dissemination experimentally.
In summary, we provide evidence for the ﬁrst time of
high heterogeneity at the gene expression level among indi-
vidual lung metastases of a dediﬀerentiated chondrosarcoma
patient. Despite this heterogeneity, we identiﬁed a set of
“multifunctional” genes that are commonly expressed in the
metastases. Also for the ﬁrst time, we documented massive
macrophage inﬁltration in the dediﬀerentiated chondrosar-
coma lung metastases. It remains to be determined if the
same phenomena will be observed in lung metastases of
other dediﬀerentiated chondrosarcoma patients. Albeit de-
rived from a single case, our ﬁndings have shed some light
to the molecular mechanisms underlying metastasis in ded-
ifferentiated chondrosarcoma.
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